Characterization of silicone pressure-sensitive adhesive episcleral implant for drug delivery

References

• Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv 2007;4:371–88
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes PM, Robinson MR. Recent advances in drug delivery systems for treating ocular complications of systemic diseases. Curr Opin Ophthalmol 2009;20:511–19
   PubMed Web of Science ®Google Scholar
• Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. APPS J 2010;12:348–60
   PubMed Web of Science ®Google Scholar
• Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004;24:676–98
   PubMed Web of Science ®Google Scholar
• Day S, Acquah K, Mruthyunjaya P, et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011;152:266–72
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Ogura Y, Kimura H, et al. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006;3:261–73
   PubMed Web of Science ®Google Scholar
• Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010;27:2043–53
   PubMed Web of Science ®Google Scholar
• Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001;52:37–48
   PubMed Web of Science ®Google Scholar
• Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57:2063–79
   PubMed Web of Science ®Google Scholar
• Lee SB, Geroski DH, Prausnitz MR, Edelhauser HF. Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems. Exp Eye Res 2004;78:599–607
   PubMed Web of Science ®Google Scholar
• Okabe K, Kimura H, Okabe J, Ogura Y. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants. Retina 2007;27:770–7
   PubMed Web of Science ®Google Scholar
• Carcaboso AM, Chiappetta DA, Opezzo JA, et al. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest Ophthalmol Vis Sci 2010;51:2126–34
   PubMed Web of Science ®Google Scholar
• Kato A, Kimura H, Okabe K, et al. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest Ophthalmol Vis Sci 2004;45:238–44
   PubMed Web of Science ®Google Scholar
• Venkatraman S, Gale R. Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems. Biomaterials 1998;19:1119–36
   PubMed Web of Science ®Google Scholar
• Tolia G, Li SK. Study of drug release and tablet characteristics of silicone adhesive matrix tablets. Eur J Pharm Biopharm 2012;82:518–25
   PubMed Web of Science ®Google Scholar
• Lim N, Vogt U. Comparison of conventional and silicone hydrogel contact lenses for bullous keratoplasty. Eye Contact Lens 2006;32:250–3
   PubMedGoogle Scholar
• Kim H, Csaky KG, Gilger BC, et al. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci 2005;46:655–62
   PubMed Web of Science ®Google Scholar
• Tolia G, Li SK. Silicone adhesive matrix of verapamil hydrochloride to provide pH-independent sustained release. AAPS PharmSciTech 2014;15:1–10
   PubMed Web of Science ®Google Scholar
• Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145–9
   PubMed Web of Science ®Google Scholar
• Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. J Control Release 2012;161:351–62
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 1987;5:23–36
   Google Scholar
• Ranta VP, Urtti A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling. Adv Drug Deliv Rev 2006;58:1164–81
   PubMed Web of Science ®Google Scholar
• Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res 2010;27:530–43
   PubMed Web of Science ®Google Scholar
• Maurice D. Review: practical issues in intravitreal drug delivery. J Ocul Pharmacol Ther 2001;17:393–401
   PubMed Web of Science ®Google Scholar
• Dunn JP, Van Natta M, Foster G, et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 2004;24:41–50
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453–60
   PubMed Web of Science ®Google Scholar
• Ambati J, Adamis AP. Transscleral drug delivery to the retina and choroid. Prog Retin Eye Res 2002;21:145–51
   PubMed Web of Science ®Google Scholar
• Felt-Baeyens O, Eperon S, Mora P, et al. Biodegradable scleral implants as new triamcinolone acetonide delivery systems. Int J Pharm 2006;322:6–12
   PubMed Web of Science ®Google Scholar
• Kadam RS, Kompella UB. Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther 2010;332:1107–20
   PubMed Web of Science ®Google Scholar
• Chopra P, Hao J, Li SK. Iontophoretic transport of charged macromolecules across human sclera. Int J Pharm 2010;388:107–13
   PubMed Web of Science ®Google Scholar
• Liu L, Wang X. Solubility-modulated monolithic osmotic pump tablet for atenolol delivery. Eur J Pharm Biopharm 2008;68:298–302
   PubMed Web of Science ®Google Scholar